UNSPSC 51282603: Cefluprenam

This classification denotes a cephalosporin antibiotic with the molecular formula C20H25FN8O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 098633Q42P, chemically known as 2-propen-1-aminium, n-(2-amino-2-oxoethyl)-3-(7-(((5-amino-1,2,4-thiadiazol-3-yl)((fluoromethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)-n-ethyl-n-methyl-, inner salt, (6r-(3(e),6-alpha,7-beta(z)))- but generally known as cefluprenam, which bears US NIH Compound Identifier 6536774.

UNSPSC 51282603 Cefluprenam is a Commodity code that nominally designates a specific antibiotic pharmaceutical, but recent state and local opportunities posted under this code show a mismatch with the code's scope. The solicitations actually reflect procurement for naloxone, medical and first aid supplies, generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs—none of which are cefluprenam. State and local governments posting these opportunities appear to be using the code as a broad catch-all for pharmaceutical and medical supply procurement rather than for cefluprenam specifically. Issuing bodies include county health departments, municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances sourcing on behalf of multiple jurisdictions and state agencies.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, response deadline July 26, 2023); the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000 with a March 13, 2026 response deadline and a designated Small Local Business Enterprise set-aside; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products serving state and local facilities across multiple states, due March 26, 2026. The code shows limited relevant recent activity aligned with its nominal pharmaceutical designation and should be treated with caution when evaluating cefluprenam-specific opportunity streams.